News - Zealand Pharma


Current filters:

Zealand Pharma

Popular Filters

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan


Denmark’s Zealand Pharma says it has achieved a milestone under its collaboration with French drug…

DiabetesFinancialLixiLanLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study


Results of a 24-week Phase IIIb clinical study showed that French drug major Sanofi’s diabetes drug…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show


Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi temporarily pulls lixisenatide NDA in USA


French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Zealand and Lilly to work together on type 2 diabetes and obesity therapies


Denmark's Zealand Pharma (Nasdaq OMX: ZEAL) has announced an exclusive peptide drug R&D collaboration…

DiabetesEli LillyGlobalPharmaceuticalResearchZealand Pharma

Helsinn and Zealand to advance elsiglutide for chemotherapy-induced diarrhea prevention


Privately-held Swiss pharmaceutical group Helsinn and its partner, Denmark-based Zealand Pharma A/S (Nasdaq:…

elsiglutideGastro-intestinalsHelsinnOncologyPharmaceuticalResearchZealand Pharma

US FDA accepts Sanofi's NDA for diabetes drug lixisenatide


The US Food and Drug Administration has accepted for review French drug major Sanofi's (Euronext: SAN)…

DiabeteslixisenatideNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"


The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

Sanofi files for Japanese approval of diabetes drug Lyxumia


French drug major Sanofi (Euronext: SAN), has submitted a marketing authorization application for lixisenatide…

Asia-PacificDiabeteslixisenatideLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Abbott Labs acquires drug candidate from Action Pharma


US health care group Abbott Laboratories (NYSE: ABT) and Action Pharma A/S, a privately-owned company…

Abbott LaboratoriesAction PharmaLicensingNephrology and HepatologyPharmaceuticalZealand Pharma

$20 million lixisenatide milestone for Zealand Pharma


Danish peptide drug discovery firm Zealand Pharma (Nasdaq OMX Copenhagen: ZEAL) says it will receive…

DiabetesFinanciallixisenatideLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma


Danish drug discovery firm Zealand Pharma (Nasdaq OMX: ZEAL.CO), says that its partner, French drug major…

DiabetesFinancialLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting


French drug major Sanofi (Euronext: SAN) has reported positive results from the GetGoal-F1 study with…

DiabetesLantusLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Back to top